Review anchor
Sodium-dependent noradrenaline transporter
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Sodium-dependent noradrenaline transporter
CHEMBL222
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Sodium-dependent noradrenaline transporter as ChEMBL target CHEMBL222, mapped to UniProt P23975. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL222
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P23975
Sodium-dependent noradrenaline transporter
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Sodium-dependent noradrenaline transporter matters
Sodium-dependent noradrenaline transporter is reviewed as Sodium-dependent noradrenaline transporter (UniProt P23975); Sodium-dependent noradrenaline transporter shows approved-linked disease relevance led by attention deficit hyperactivity disorder. 5 more disease programs remain visible in the same review block.; 16 linked drugs keep this evidence frame grounded.; the current evidence base includes 223 approved drugs, 7374 compounds, and 864 assays, with lead potency reaching pChEMBL 10.2.
Protein context
Sodium-dependent noradrenaline transporter
Sodium-dependent noradrenaline transporter Sequence length is 617 aa.
Review this target as Sodium-dependent noradrenaline transporter, mapped to UniProt P23975. Sequence length is 617 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P23975
Protein
Disease context
attention deficit hyperactivity disorder
Sodium-dependent noradrenaline transporter shows approved-linked disease relevance led by attention deficit hyperactivity disorder. 5 more disease programs remain visible in the same review block. 16 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AMPHETAMINE, AMPHETAMINE ASPARTATE, AMPHETAMINE SULFATE.
Start review with attention deficit hyperactivity disorder because it currently carries approved-linked support. Linked drugs include AMPHETAMINE, AMPHETAMINE ASPARTATE, AMPHETAMINE SULFATE, AMPRELOXETINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
16 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 223 approved drugs, 7374 compounds, and 864 assays for this target. The dominant activity type is IC50. CHEMBL3819243 is the current potency anchor at pChEMBL 10.2.
Use CHEMBL3819243 as the tractability anchor when discussing potency (pChEMBL 10.2).
Activity source · ChEMBL 36 via Core Engine
223 approved
pChEMBL 10.2
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Sodium-dependent noradrenaline transporter matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P23975, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why attention deficit hyperactivity disorder is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
7374
Total Compounds
864
Total Assays
223
Approved Drugs
IC50: 3602.0, KI: 3473.0, EC50: 55.0, KD: 28.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3819243
|
10.2 | IC50 | — |
|
|
No preferred name
CHEMBL4228464
|
10.1 | Ki | — |
|
|
No preferred name
CHEMBL3819201
|
10.1 | IC50 | — |
|
|
No preferred name
CHEMBL3818117
|
10.1 | IC50 | — |
|
|
No preferred name
CHEMBL3817915
|
10.0 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
VILOXAZINE
CHEMBL306700
|
2021 |
|
|
COCAINE
CHEMBL370805
|
2017 |
|
|
COCAINE HYDROCHLORIDE
CHEMBL529437
|
2017 |
|
|
BREXPIPRAZOLE
CHEMBL2105760
|
2015 |
|
|
LEVOMILNACIPRAN
CHEMBL99946
|
2013 |
|
|
VILAZODONE HYDROCHLORIDE
CHEMBL1615374
|
2011 |
|
|
VILAZODONE
CHEMBL439849
|
2011 |
|
|
MILNACIPRAN
CHEMBL259209
|
2009 |
|
|
INDACATEROL
CHEMBL1095777
|
2009 |
|
|
DESVENLAFAXINE
CHEMBL1118
|
2008 |
|
|
DULOXETINE
CHEMBL1175
|
2004 |
|
|
ATOMOXETINE
CHEMBL641
|
2002 |
|
|
ATOMOXETINE HYDROCHLORIDE
CHEMBL1702
|
2002 |
|
|
RALOXIFENE
CHEMBL81
|
1997 |
|
|
REBOXETINE
CHEMBL14370
|
1997 |
|
|
TRAMADOL
CHEMBL1237044
|
1995 |
|
|
CARVEDILOL
CHEMBL723
|
1995 |
|
|
NEFAZODONE
CHEMBL623
|
1994 |
|
|
NEFAZODONE HYDROCHLORIDE
CHEMBL1200492
|
1994 |
|
|
SALMETEROL
CHEMBL1263
|
1994 |
|
|
VENLAFAXINE
CHEMBL637
|
1993 |
|
|
TACRINE
CHEMBL95
|
1993 |
|
|
PAROXETINE
CHEMBL490
|
1992 |
|
|
SERTRALINE
CHEMBL809
|
1991 |
|
|
EBASTINE
CHEMBL305660
|
1990 |
|
|
CLOMIPRAMINE
CHEMBL415
|
1989 |
|
|
FLUOXETINE
CHEMBL41
|
1987 |
|
|
BUPROPION
CHEMBL894
|
1985 |
|
|
NOMIFENSINE
CHEMBL273575
|
1984 |
|
|
ETHINYL ESTRADIOL
CHEMBL691
|
1982 |
|
|
MAPROTILINE HYDROCHLORIDE
CHEMBL1237135
|
1980 |
|
|
AMOXAPINE
CHEMBL1113
|
1980 |
|
|
MAPROTILINE
CHEMBL21731
|
1980 |
|
|
DOBUTAMINE
CHEMBL926
|
1978 |
|
|
DOPAMINE
CHEMBL59
|
1974 |
|
|
MAZINDOL
CHEMBL781
|
1973 |
|
|
MITOTANE
CHEMBL1670
|
1970 |
|
|
DOXEPIN
CHEMBL1628227
|
1969 |
|
|
PROTRIPTYLINE
CHEMBL668
|
1967 |
|
|
NORTRIPTYLINE
CHEMBL445
|
1964 |
|
|
DESIPRAMINE HYDROCHLORIDE
CHEMBL1696
|
1964 |
|
|
NORTRIPTYLINE HYDROCHLORIDE
CHEMBL1201156
|
1964 |
|
|
DESIPRAMINE
CHEMBL72
|
1964 |
|
|
CYPROHEPTADINE
CHEMBL516
|
1961 |
|
|
AMITRIPTYLINE HYDROCHLORIDE
CHEMBL1200964
|
1961 |
|
|
AMITRIPTYLINE
CHEMBL629
|
1961 |
|
|
IMIPRAMINE
CHEMBL11
|
1959 |
|
|
CHLORPROMAZINE
CHEMBL71
|
1957 |
|
|
PROCHLORPERAZINE
CHEMBL728
|
1956 |
|
|
PROMAZINE
CHEMBL564
|
1956 |
Source Header